Rezdiffra contains resmetirom, an oral medicine approved with diet and exercise for adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with F2–F3. The indication uses accelerated approval, with confirmatory clinical benefit still required.
Discover Nao Medical's virtual care solutions for occupational health. From wellness checkups to mental health support, boost productivity with care from anywhere.
Rezdiffra contains resmetirom, an oral medicine approved with diet and exercise for adults with noncirrhotic MASH and moderate-to-advanced fibrosis consistent with F2–F3. The indication uses accelerated approval, with confirmatory clinical benefit still required.
Resmetirom activates thyroid hormone receptor beta in the liver. It is not a GLP-1 medicine or a weight-loss product. Its mechanism and interaction profile differ from Wegovy.
Eligibility needs the correct liver diagnosis and fibrosis stage. An ultrasound showing fatty liver alone is insufficient. Decompensated cirrhosis is a limitation of use and requires separate specialist care.
Confirm diagnosis and fibrosis evidence, then review liver tests and interacting medicines. Dose is weight-based, with modifications for certain interactions. The prescriber reviews CYP2C8 inhibitors and statin limits before treatment. Discuss the nutrition, activity, laboratory, and follow-up plan.
Bring imaging, fibrosis tests, biopsy results if present, liver tests, medicines including statins and clopidogrel, and insurance requirements. Include prior hepatology notes.
Hepatotoxicity, gallbladder reactions, and statin interactions are important risks. New jaundice, severe right-sided abdominal pain, or other liver symptoms needs prompt medical assessment. Do not combine treatments without prescriber review.
Monitor liver symptoms and laboratory tests as the clinician directs. Review gallbladder symptoms, interaction-related effects, and fibrosis follow-up. Weight loss alone does not prove treatment success.
Confirm the exact service, clinician, formulation, appointment, and refill route before booking. The evaluation, tests, medicine, administration, and follow-up may have separate costs and benefits. Ask for current estimates and required records. An FDA-approved drug or a clinic address does not establish pharmacy stock, onsite treatment, coverage, or a prescription. If access changes, contact the treating team before interrupting treatment.
No. The Wegovy MASH indication belongs to the injection. Wegovy tablets have adult weight and qualifying cardiovascular indications, not the injection’s MASH indication. Product choice must follow the exact formulation’s label.
No. Liver fat on imaging does not by itself establish noncirrhotic MASH with F2–F3 fibrosis. The clinician reviews diagnosis, severity, and other causes before deciding whether Rezdiffra or Wegovy injection’s MASH indication fits.
A clinician must review the liver diagnosis, fibrosis stage, metabolic needs, side effects, and interactions before combining Rezdiffra with a GLP-1 medicine. The labels do not establish that every patient should use the combination. Keep specialist follow-up and do not add or switch treatments yourself.
No. Improved weight or normal liver enzymes does not prove that fibrosis has resolved. Keep the clinician’s liver and fibrosis follow-up plan. Tests and symptoms are interpreted together.
Bring imaging, fibrosis tests, biopsy results if present, liver tests, medicines including statins and clopidogrel, and insurance requirements. Include prior hepatology notes.
Rezdiffra is not approved as a weight-loss medicine. Its approved purpose is treatment of adults with noncirrhotic MASH and moderate to advanced fibrosis consistent with F2–F3, alongside diet and exercise. Its liver-directed thyroid hormone receptor-beta action differs from GLP-1 weight medicines. Weight may change during a combined nutrition and treatment plan, but weight loss alone does not show that liver fibrosis has improved. Unexpected or substantial weight loss deserves review, particularly if diarrhea or other symptoms are affecting intake. Discuss weight treatment and MASH monitoring as related but separate goals.
Your cost depends on the prescribed treatment, insurance coverage and any assistance for which you qualify. As of October 9, 2026, Madrigal advertises a Rezdiffra copay savings program for eligible commercially insured patients; people enrolled in Medicare, Medicaid or other government programs cannot use that commercial offer. Madrigal Patient Support or the dispensing specialty pharmacy can review coverage, eligibility and the expected medication charge before delivery. This does not guarantee insurance approval or a particular bill. Confirm visit and test charges separately with the care team.
Choose care according to the problem and how urgently you need help. Urgent care assesses non-emergency illnesses and minor injuries.
